FDA approves Egetis’ Emcitate for rare genetic disease as Novo secures Chinese weight-loss pill in $2.6 billion deal

The U.S. Food and Drug Administration has granted approval to Egetis' Emcitate, a therapy targeting a rare genetic disorder. This marks a regulatory milestone for the company and patients awaiting treatment.

In a parallel development, Novo has agreed to purchase the rights to a Chinese weight‑loss pill, sealing a transaction valued at approximately $2.6 billion. The deal expands Novo's portfolio in the obesity market.

Regulatory experts note that early engagement with the FDA and careful preparation of biologics license applications are critical steps that can facilitate approvals such as the one announced for Emcitate.